期刊
IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA
卷 30, 期 2, 页码 195-+出版社
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.iac.2010.01.003
关键词
Immunodeficiency; High-risk patient; RIC regimen; In vivo T-depletion
Chronic granulomatous disease (CGD) is a primary immunodeficiency disease that is caused by the lack of 1 of 5 subunits of the superoxide-producing nicotinamide adenine. dinucleotide phosphate oxidase of neutrophils, macrophages, and eosinophils. Allogeneic hematopoietic stem cell transplantation (HSCT) is currently the only curative treatment for CGD and can be offered to selected patients. Improved outcome with supportive care and high clinical variability in the disease course, however, make selection of eligible patients for HSCT difficult. This article addresses recent progress in HSCT for CGD, delineates present limitations, and points to future developments.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据